Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
29 publications sur 5 ans↗
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
8
8 articles ont été cités au moins 8fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
138
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
31
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
6
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université Claude Bernard Lyon 1 · Centre National de la Recherche Scientifique · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Contralateral R1 response in blink reflex in patients with amyotrophic lateral sclerosis
2025ArticleClinical neurophysiology practice
Demyelinating neuropathy as the initial presentation of familial E200K Creutzfeldt–Jakob disease in two patients
2025ArticleAnnals of Clinical and Translational Neurology
Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis
2024ArticleBrain - A Journal of Neurology
Defining the landscape of TIA1 and SQSTM1 digenic myopathy
2024ArticleNeuromuscular Disorders
A previously unreported NARS1 variant causes dominant distal hereditary motor neuropathy in a French family
2024ArticleJournal of the Peripheral Nervous System
Genetic characterization of non-5q proximal spinal muscular atrophy in a French cohort: the place of whole exome sequencing.
2024ArticleEuropean Journal of Human Genetics
Reply: Biallelic variants in the COQ7 gene cause distal hereditary motor neuropathy in two Chinese families
2023ArticleBrain - A Journal of Neurology
Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy
2022ArticleBrain - A Journal of Neurology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL PIERRE WERTHEIMER - HCL
59 BD PINEL, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of neurology · 2023
AbstractBackgroundGlial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also by immature and regenerative Schwann cells in the peripheral nervous system (PNS). GFAP antibodies (GFAP-Abs) in cerebrospinal fluid (CSF) have been mainly described in patients with meningoencephalomyelitis. We aimed to study PNS symptoms in patients with CSF GFAP-Abs.MethodsWe retrospectively included all patients tested positive for GFAP-Abs in the CSF by immunohistochemistry and confirmed by cell-based assay expressing human GFAPα since 2017, from two French reference centers.ResultsIn a cohort of 103 CSF GFAP-Abs patients, 25 (24%) presented with PNS involvement. Among them, the median age at onset was 48 years and 14/25 (56%) were female. Abnormal electroneuromyography was observed in 11/25 patients (44%), including eight isolated radiculopathies, one radiculopathy associated with polyneuropathy, one radiculopathy associated with sensory neuronopathy, and one demyelinating polyradiculoneuropathy. Cranial nerve involvement was observed in 18/25 patients (72%). All patients except one had an associated CNS involvement. The first manifestation of the disease concerned the PNS in three patients. First-line immunotherapy was administered to 18/24 patients (75%). The last follow-up modified Rankin Scale was ≤ 2 in 19/23 patients (83%). Patients with PNS involvement had significantly more bladder dysfunction than patients with isolated CNS involvement (68 vs 40.3%,p = 0.031).ConclusionsPNS involvement in GFAP-Abs autoimmunity is heterogeneous but not rare and is mostly represented by acute or subacute cranial nerve injury and/or lower limb radiculopathy. Rarely, PNS involvement can be the first manifestation revealing the disease.
Genes · 2022
X-linked Myopathy with Excessive Autophagy (XMEA) is a rare autophagic vacuolar myopathy caused by mutations in the Vacuolar ATPase assembly factor VMA21 gene; onset usually occurs during childhood and rarely occurs during adulthood. We described a 22-year-old patient with XMEA, whose onset was declared at 11 through gait disorder. He had severe four-limb proximal weakness and amyotrophy, and his proximal muscle MRC score was between 2 and 3/5 in four limbs; creatine kinase levels were elevated (1385 IU/L), and electroneuromyography and muscle MRI were suggestive of myopathy. Muscle biopsy showed abnormalities typical of autophagic vacuolar myopathy. We detected a hemizygous, unreported, intronic, single-nucleotide substitution c.164-20T>A (NM_001017980.4) in intron 2 of the VMA21 gene. Fibroblasts derived from this patient displayed a reduced level of VMA21 transcripts (at 40% of normal) and protein, suggesting a pathogenicity related to an alteration of the splicing efficiency associated with an intron retention. This patient with XMEA displayed a severe phenotype (rapid weakness of upper and lower limbs) due to a new intronic variant of VMA21, related to an alteration in the splicing efficiency associated with intron retention, suggesting that phenotype severity is closely related to the residual expression of the VMA21 protein.
European journal of neurology · 2025
ABSTRACTBackgroundThis study aimed to investigate the prevalence, characteristics, and determinants of peripheral neuropathy in a large cohort of patients affected by spinocerebellar ataxia type 27B (SCA27B), a late‐onset cerebellar ataxia caused by heterozygous GAA repeat expansions in the first intron of the FGF14 gene.MethodsA retrospective, multicenter study in which medical records of SCA27B patients diagnosed between January 2023 and July 2024 in 21 French ataxia/neurogenetic centers were reviewed. Those who had undergone electrodiagnostic study were included.ResultsAmong 332 SCA27B patients, 170 had undergone an electrodiagnostic study and were included. Forty‐two (25%) were diagnosed with neuropathy: 16 with length‐dependent axonal sensorimotor neuropathy, 24 with length‐dependent axonal sensory neuropathy, one with sensory, and one with motor neuronopathy. Neuropathy was associated with male sex, older age at electrodiagnostic study, and risk factors for neuropathy but not with GAA expansion sizes. Patients with neuropathy had more severe disability at the last visit (median SARA score 12 vs. 8, p = 0.0024).ConclusionsThe prevalence of neuropathy in SCA27B patients was similar to that reported in the elderly general population. Neuropathies were predominantly non‐specific length‐dependent axonal neuropathies, primarily driven by aging and known risk factors rather than the underlying genetic abnormality.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of neurology · 2026 · Journal Article
Theuriet J, Michaud M, Fargeot G, Labeyrie C, et al.
Journal of the peripheral nervous system : JPNS · 2024 · Case Reports
Theuriet J, Gerfaud-Valentin M, Durel CA, Gouya L, et al.
Genes · 2022 · Case Reports
Pegat A, Streichenberger N, Lacoste N, Hermier M, et al.
Annals of clinical and translational neurology · 2025 · Journal Article
Delorme C, Pégat A, Theuriet J, Brandel JP, et al.
Neurophysiologie clinique = Clinical neurophysiology · 2024 · Case Reports
Theuriet J, Huchon L, Luaute J, Vallet AE, et al.
Journal of neurology · 2023 · Journal Article
Theuriet J, Cluse F, Gravier-Dumonceau A, Picard G, et al.
European journal of neurology · 2025 · Journal Article
Theuriet J, Paulet L, Acket B, Ory-Magne F, et al.
European journal of human genetics : EJHG · 2024 · Journal Article
Theuriet J, Fernandez-Eulate G, Latour P, Stojkovic T, et al.
Muscle & nerve · 2025 · Journal Article
Theuriet J, Bernard E, Guy N, Taithe F, et al.